Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Immunovant Inc (Symbol: IMVT), where a total volume of 6,555 contracts has been traded thus far today, a contract volume which is representative of approximately 655,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 44.2% of IMVT's average daily trading volume over the past month, of 1.5 million shares. Particularly high volume was ...

A month has gone by since the last earnings report for Immunovant, Inc. (IMVT) . Shares have added about 7.8% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Immunovant due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.Immunovant’s Q1 Loss Narrower Than Expected, Pipel ...

Core Insights - Immunovant, Inc. (IMVT) shares increased by 10.8% following the announcement of six-month off-treatment results from a proof-of-concept study for batoclimab in patients with uncontrolled Graves' disease (GD) [1][4] - The study demonstrated that approximately 80% of patients maintained normalized thyroid hormone levels during the follow-up period, indicating strong durability of response [3][4] Study Details - The proof-of-concept study involved patients with active GD who had elevated thyroid hormone levels despite antithyroid drug (ATD) therapy. The primary endpoint was the normalization or reduction of thyroid hormone levels without increasing ATD dosage at week 24 [2] - Among the responders, about half achieved ATD-free remission, while 30% required only minimal ATD doses of 2.5 mg/day [6] Implications and Future Plans - The findings suggest that FcRn blockade may provide a promising therapeutic approach for GD, with potential for disease modification as several patients achieved durable remission after treatment withdrawal [7] - Immunovant plans to leverage the batoclimab data to expedite the development of its lead candidate, IMVT-1402, which is also aimed at treating GD [8] - The company has initiated two global studies for IMVT-1402, evaluating a 600 mg dose for up to 52 weeks, with top-line results expected in 2027 [9]

PresentationGood day, and thank you for standing by. Welcome to the Immunovant Graves' Disease Data Update Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the call over to your first speaker today, Stephanie Lee. Please go ahead.Stephanie Lee GriffinChief Operating Officer of Roivant Platforms Good afternoon, and thanks for joining today's call to review the Immunovant Graves' disease data. I'm Stephanie Lee with Roivant. Presenting today, ...

Core Insights - Immunovant's shares increased nearly 11% following positive laboratory results, outperforming the S&P 500's 0.5% rise [1] Group 1: Clinical Study Results - Immunovant presented data from a proof-of-concept study for its investigational drug batoclimab, targeting Grave's disease, an autoimmune disorder characterized by excessive thyroid hormone production [2] - The study lasted almost one year, with 17 out of 21 patients maintaining normal thyroid function six months post-treatment, and 8 of these patients no longer requiring anti-thyroid medications [4] Group 2: Management and Future Prospects - CEO Eric Venker stated that the data could be transformative for patients and practice-changing for physicians if approved by the FDA, addressing a significant unmet need in Grave's disease [5] - Batoclimab is being explored for other conditions, including Sjögren's syndrome, indicating the drug's potential flexibility and broader application [5]

Core Insights - Immunovant, Inc. presented six-month off-treatment data for batoclimab in uncontrolled Graves' disease patients, indicating potential disease modification and strong durability of response [1][2][3] Study Details - The proof-of-concept study involved a 24-week treatment with batoclimab, followed by a 24-week off-treatment follow-up, focusing on patients with active Graves' disease [3][4] - Key endpoint was the normalization of free triiodothyronine (T3) and free thyroxine (T4) levels at Week 24 without increasing anti-thyroid drug (ATD) doses from baseline [3] Remission Data - Out of 21 patients in the follow-up, approximately 80% (17/21) maintained normal thyroid function after six months off treatment [6][7] - Among responders, about 50% (8/17) achieved ATD-free remission, while an additional 30% (5/17) were on low ATD doses [6][7] Future Trials - Two potentially registrational trials for IMVT-1402 in Graves' disease are currently enrolling, with topline readouts expected in 2027 [5][6]

Core Insights - Immunovant, Inc. presented six-month off-treatment data for batoclimab in uncontrolled Graves' disease patients, indicating potential disease modification and strong durability of response [1][2][3] Study Details - The proof-of-concept study involved a 24-week treatment with batoclimab, followed by a 24-week off-treatment follow-up, focusing on patients with active Graves' disease [3][4] - The key endpoint was the normalization of free triiodothyronine (T3) and free thyroxine (T4) levels without increasing anti-thyroid drug (ATD) doses from baseline [3] Remission Data - Out of 21 patients in the follow-up period, approximately 80% (17/21) maintained normal thyroid function at the end of six months [6][7] - Among the responders, about 50% (8/17) achieved ATD-free remission, while an additional 30% (5/17) were on low ATD doses [6][7] Future Trials - Two potentially registrational trials for Immunovant's lead compound IMVT-1402 in Graves' disease are currently enrolling, with topline readouts expected in 2027 [5][6]

Core Points - The article does not provide any specific insights or analysis related to a company or industry, focusing instead on the author's credentials and disclosures [1][2][3] Group 1 - The author holds multiple degrees in engineering, computer science, business management, and computer applications from various institutions [1] - The author collaborates with another individual but emphasizes independent analysis and adherence to guidelines [1] - There are no disclosed positions in any mentioned companies, and the author does not plan to initiate any positions in the near future [2]

Core Insights - Immunovant, Inc. reported a first-quarter fiscal 2026 adjusted net loss of $0.60 per share, which is narrower than the Zacks Consensus Estimate of a loss of $0.69 and matches the loss from the same quarter last year [1][4] Financial Performance - Research and development expenses reached $101.2 million, reflecting a 34% increase from the previous year, driven by clinical study activities for IMVT-1402 and higher personnel costs, partially offset by reduced costs in batoclimab studies [2] - General and administrative expenses were $26 million, up 38% year over year, primarily due to increased personnel-related expenses [3] - As of June 30, 2025, the company had a cash balance of $598.9 million, down from $714 million as of March 31, 2025, with expectations to fund clinical activities through 2027 [3] Pipeline Developments - IMVT-1402 is the lead drug candidate, being studied for six indications, with key data readouts expected through 2027 [4][6] - The company plans to initiate clinical studies for IMVT-1402 in a total of 10 indications by March 31, 2026, leveraging existing data from batoclimab studies for financial efficiencies [5] - During the first quarter of fiscal 2026, Immunovant initiated a second potentially registrational study of IMVT-1402 for Graves' disease and a study for Sjögren's disease [7] Upcoming Milestones - In 2026, the company plans to share open-label data from its difficult-to-treat rheumatoid arthritis study and top-line results from the cutaneous lupus erythematosus proof-of-concept study [7] - Top-line results from potentially registrational studies in difficult-to-treat rheumatoid arthritis, Graves' disease, and myasthenia gravis are expected in 2027 [7] Additional Candidates - Immunovant is also evaluating batoclimab in mid-late-stage studies for Graves' disease and thyroid eye disease, with new proof-of-concept data expected to be reported in September 2025 [8][10]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38906 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 IMMUNOVANT, INC. (Exact name of registrant as specified in its charter) Delaware 83-2771572 (State or other jurisdiction of incorporation o ...